Glycated hemoglobin or A1C is a blood test that shows the average level of blood sugar over the previous 2 to 3 months. A1C is reported as a percent. eAG is reported in mg/dL (mmol/L). This is the same measurement used in home blood sugar meters. eAG is calculated directly from your A1C results.
EAG is a measurement of your blood sugar over time and helps diabetics understand how well you are managing your blood sugar. It is based on your HbA1c results. While your glucose meter measures your blood sugar at the time of testing, EAG is the average of your blood glucose for the previous 2–3 months.
09: Other abnormal glucose.
The ICD-10 code for prediabetes is R73. 09.
That corresponds to an A1C test result that's less than 7 percent. The ADA defines the following eAG ranges: Normal range: less than 114 mg/dL. Prediabetes range: greater than 114 mg/dL and less than 140 mg/dL.
The A1C test is a blood test that provides information about your average levels of blood glucose, also called blood sugar, over the past 3 months. The A1C test can be used to diagnose type 2 diabetes and prediabetes. The A1C test is also the primary test used for diabetes management.
ICD-10 code R73. 03 for Prediabetes is a medical classification as listed by WHO under the range - Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified .
Diabetes Hemoglobin A1c Testing Claims including procedure code 83036 or 83037 should include a line item with the resulting CPT procedure code below and be billed with a zero charge.
ICD-9 Code Transition: 780.79 Code R53. 83 is the diagnosis code used for Other Fatigue. It is a condition marked by drowsiness and an unusual lack of energy and mental alertness. It can be caused by many things, including illness, injury, or drugs.
“HbA1c may be used for the diagnosis of diabetes, with values >6.5% being diagnostic.
82947 Glucose; quantitative, blood (except reagent strip) 82948 Glucose; blood, reagent strip 82962 Glucose, blood by glucose monitoring device cleared by FDA for home use.
The glycosylated hemoglobin test shows what a person's average blood glucose level was for the 2 to 3 months before the test. This can help determine how well a person's diabetes is being controlled over time. /content/kidshealth/misc/medicalcodes/parents/articles/hba1c.
The relationship between A1C and eAG is described by the formula 28.7 X A1C – 46.7 = eAG.
However, in an epidemiological study, it has been concluded that FBS is more accurate than HbA1c. The best cutoff point for defining high HbA1c is another important issue. The Diabetes Control and Complications Trial suggested the value of 6% as HbA1c cut point.
“While the American Diabetes Association guidelines specify that diabetes can be diagnosed based on fasting plasma glucose (FPG), the OGTT, or the A1c, our findings confirm that reliance on A1c remains the least reliable method for assessing diabetes risk.”
Your A1C Result A normal A1C level is below 5.7%, a level of 5.7% to 6.4% indicates prediabetes, and a level of 6.5% or more indicates diabetes.
The 2022 edition of ICD-10-CM R73.9 became effective on October 1, 2021.
Higher than normal amount of glucose (a type of sugar) in the blood. Hyperglycemia can be a sign of diabetes or other conditions.
Glycated hemoglobin in whole blood assesses glycemic control over a period of 4-8 weeks and appears to be the more appropriate test for monitoring a patient who is capable of maintaining long-term, stable control. Measurement may be medically necessary every 3 months to determine whether a patient's metabolic control has been on average within the target range. More frequent assessments, every 1-2 months, may be appropriate in the patient whose diabetes regimen has been altered to improve control or in whom evidence is present that intercurrent events may have altered a previously satisfactory level of control (for example, post-major surgery or as a result of glucocorticoid therapy). Glycated protein in serum/plasma assesses glycemic control over a period of 1-2 weeks. It may be reasonable and necessary to monitor glycated protein monthly in pregnant diabetic women. Glycated hemoglobin/protein test results may be low, indicating significant, persistent hypoglycemia, in nesidioblastosis or insulinoma, conditions which are accompanied by inappropriate hyperinsulinemia. A below normal test value is helpful in establishing the patient's hypoglycemic state in those conditions.
Glycated hemoglobin/protein testing is widely accepted as medically necessary for the management and control of diabetes. It is also valuable to assess hyperglycemia, a history of hyperglycemia or dangerous hypoglycemia. Glycated protein testing may be used in place of glycated hemoglobin in the management of diabetic patients, and is particularly useful in patients who have abnormalities of erythrocytes such as hemolytic anemia or hemoglobinopathies.
The management of diabetes mellitus requires regular determinations of blood glucose levels. Glycated hemoglobin/protein levels are used to assess long-term glucose control in diabetes. Alternative names for these tests include glycated or glycosylated hemoglobin or Hgb, hemoglobin glycated or glycosylated protein, and fructosamine.
When the glycated hemoglobin assay is initially performed in these patients, the laboratory may inform the ordering physician of a possible analytical interference. Alternative testing, including glycated protein, for example, fructosamine, may be indicated for the monitoring of the degree of glycemic control in this situation. It is therefore conceivable that a patient will have both a glycated hemoglobin and glycated protein ordered on the same day. This should be limited to the initial assay of glycated hemoglobin, with subsequent exclusive use of glycated protein. These tests are not considered to be medically necessary for the diagnosis of diabetes.
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Pediatric EDTA whole blood tubes may be used. Please place original labeled capillary tube in a labeled transport tube for shipment to the laboratory. ( Note: This volume does not allow for repeat testing.)
Lavender-top (EDTA) tube, green-top (lithium heparin) tube, or gray-top (sodium fluoride) tube
The usual precautions in the collection of venipuncture samples should be observed. The sample must be free of clots. Samples with any hematocrit disorders can lead to erroneous results. Send the entire tube to the laboratory.
Any cause of shortened erythrocyte survival will reduce exposure of erythrocytes to glucose with a consequent decrease in Hb A 1c (%). Causes of shortened erythrocyte lifetime might be hemolytic anemia or other hemolytic diseases, homozygous sickle cell trait, pregnancy, or recent significant or chronic blood loss.
Factors such as duration of diabetes, adherence to therapy, and age of patient should also be considered in assessing the degree of blood glucose control.